Skip to main content

Novartis Ag ADR(NVS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low96.15
Day High97.20
Open:96.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Investor Brand Network
Scinai Immunotherapeutics (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
Newswire.ca
Biotech Executive Meenu Chhabra Karson joins Bedford Group Transearch Advisory Board
Newswire.ca
RB Global Appoints Eric J. Guerin as Chief Financial Officer
Newswire.ca
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
Newswire.ca
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORS
Newswire.ca
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK AS CHIEF MEDICAL OFFICER
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Investor Brand Network
Scinai Immunotherapeutics (NASDAQ: SCNI) Reports Promising Results in Pursuit of Treatments for Plaque Psoriasis Patients

Profile

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.